Sample deck
A complete deck, built from one abstract
Fictional trial, real structure: ten slides covering the question, design, baseline, intervention and outcomes, with the charts drawn from the reported numbers. Move through it with the arrows, and export it in any format.
High-flow nasal oxygen in acute hypoxemic respiratory failure
The HiFlo-ICU randomized trial
Use the arrow keys to move through the deck.
High-flow nasal oxygen in acute hypoxemic respiratory failure
The HiFlo-ICU randomized trial
The question in five parts
Adults admitted to an ICU with acute hypoxemic respiratory failure (PaO2/FiO2 < 300) who did not need immediate intubation
High-flow nasal oxygen at 50 L/min, FiO2 titrated to SpO2 92-96%, continued until weaning criteria met
Conventional oxygen by non-rebreather mask at 15 L/min with the same SpO2 target
Primary: intubation within 28 days. Secondary: ICU length of stay, 90-day mortality, patient comfort
Multicenter (12 ICUs), open-label randomized controlled trial, 1:1 allocation with concealed assignment, blinded outcome adjudication, intention-to-treat analysis
Absolute risk reduction 12.0% (95% CI 4.1 to 19.9), p = 0.03; NNT 9
What the trial set out to answer
- Whether early high-flow nasal oxygen reduces the need for endotracheal intubation compared with conventional oxygen therapy
- Hypothesis: HFNO lowers intubation by improving alveolar recruitment and reducing work of breathing
- Secondary aim: compare ICU length of stay, mortality and patient-reported comfort
Multicenter, open-label, randomized controlled trial
- Adults randomized 1:1 within 6 hours of ICU admission using a central web-based system with permuted blocks
- Allocation concealed; outcome adjudicators blinded to treatment arm
- Primary endpoint: intubation within 28 days, adjudicated by two independent clinicians
- Powered for a 12% absolute reduction in intubation (80% power, two-sided alpha 0.05)
Patient disposition
- Lost to follow-up n = 3
- Analysed n = 303
- Lost to follow-up n = 5
- Analysed n = 301
Groups were well balanced at enrollment
| Characteristic | HFNO (n = 306) | Conventional O2 (n = 306) |
|---|---|---|
| Age, years (mean ± SD) | 64 ± 13 | 65 ± 12 |
| Male sex | 58% | 61% |
| APACHE II (mean ± SD) | 21 ± 6 | 22 ± 6 |
| PaO2/FiO2 ratio | 187 ± 53 | 190 ± 48 |
| Vasopressors at baseline | 24% | 22% |
| Pneumonia as cause | 63% | 60% |
No clinically meaningful difference between arms
How high-flow nasal oxygen was delivered
- Flow started at 50 L/min and adjusted between 40 and 60 L/min for comfort
- FiO2 titrated to SpO2 92-96%, weaned by 5 L/min every 4 hours once stable
- Protocolized escalation: intubation if FiO2 > 0.9, respiratory rate > 35, or pH < 7.30
- Nurses recorded device tolerance and comfort (0-10 scale) every 4 hours
Fewer intubations, shorter ICU stay
Intubation HR 0.68 (95% CI 0.52 to 0.89), p = 0.005
Oxygenation improved faster with HFNO
Mean difference at 24 h: 54 mmHg (95% CI 38 to 70), p < 0.001
What this means for the ward tonight
- HFNO reduced intubation by 12 percentage points: one intubation avoided for every 9 patients treated
- Benefit was consistent across pneumonia and non-pneumonia subgroups
- Mortality signal favored HFNO but the trial was not powered for mortality
- Reasonable first-line support in hypoxemic failure when intubation is not yet indicated
Read these results with care
- Open-label design: clinicians knew the arm, which may influence the intubation decision
- Single primary endpoint; secondary outcomes are exploratory and unadjusted
- Excluded patients with hypercapnia, so findings do not extend to COPD exacerbation
- Industry funding for device provision; authors report no control over analysis
Start high-flow oxygen early in hypoxemic failure
Early HFNO cut intubation by 12 points and improved oxygenation within 24 hours in adults with acute hypoxemic respiratory failure.
- One intubation was avoided for every 9 patients treated with HFNO instead of conventional oxygen.
- Mortality did not differ, so the decision rests on avoiding intubation and its complications.
High-flow nasal oxygen in acute hypoxemic respiratory failure
The HiFlo-ICU randomized trial
The question in five parts
Adults admitted to an ICU with acute hypoxemic respiratory failure (PaO2/FiO2 < 300) who did not need immediate intubation
High-flow nasal oxygen at 50 L/min, FiO2 titrated to SpO2 92-96%, continued until weaning criteria met
Conventional oxygen by non-rebreather mask at 15 L/min with the same SpO2 target
Primary: intubation within 28 days. Secondary: ICU length of stay, 90-day mortality, patient comfort
Multicenter (12 ICUs), open-label randomized controlled trial, 1:1 allocation with concealed assignment, blinded outcome adjudication, intention-to-treat analysis
Absolute risk reduction 12.0% (95% CI 4.1 to 19.9), p = 0.03; NNT 9
What the trial set out to answer
- Whether early high-flow nasal oxygen reduces the need for endotracheal intubation compared with conventional oxygen therapy
- Hypothesis: HFNO lowers intubation by improving alveolar recruitment and reducing work of breathing
- Secondary aim: compare ICU length of stay, mortality and patient-reported comfort
Multicenter, open-label, randomized controlled trial
- Adults randomized 1:1 within 6 hours of ICU admission using a central web-based system with permuted blocks
- Allocation concealed; outcome adjudicators blinded to treatment arm
- Primary endpoint: intubation within 28 days, adjudicated by two independent clinicians
- Powered for a 12% absolute reduction in intubation (80% power, two-sided alpha 0.05)
Patient disposition
- Lost to follow-up n = 3
- Analysed n = 303
- Lost to follow-up n = 5
- Analysed n = 301
Groups were well balanced at enrollment
| Characteristic | HFNO (n = 306) | Conventional O2 (n = 306) |
|---|---|---|
| Age, years (mean ± SD) | 64 ± 13 | 65 ± 12 |
| Male sex | 58% | 61% |
| APACHE II (mean ± SD) | 21 ± 6 | 22 ± 6 |
| PaO2/FiO2 ratio | 187 ± 53 | 190 ± 48 |
| Vasopressors at baseline | 24% | 22% |
| Pneumonia as cause | 63% | 60% |
No clinically meaningful difference between arms
How high-flow nasal oxygen was delivered
- Flow started at 50 L/min and adjusted between 40 and 60 L/min for comfort
- FiO2 titrated to SpO2 92-96%, weaned by 5 L/min every 4 hours once stable
- Protocolized escalation: intubation if FiO2 > 0.9, respiratory rate > 35, or pH < 7.30
- Nurses recorded device tolerance and comfort (0-10 scale) every 4 hours
Fewer intubations, shorter ICU stay
Intubation HR 0.68 (95% CI 0.52 to 0.89), p = 0.005
Oxygenation improved faster with HFNO
Mean difference at 24 h: 54 mmHg (95% CI 38 to 70), p < 0.001
What this means for the ward tonight
- HFNO reduced intubation by 12 percentage points: one intubation avoided for every 9 patients treated
- Benefit was consistent across pneumonia and non-pneumonia subgroups
- Mortality signal favored HFNO but the trial was not powered for mortality
- Reasonable first-line support in hypoxemic failure when intubation is not yet indicated
Read these results with care
- Open-label design: clinicians knew the arm, which may influence the intubation decision
- Single primary endpoint; secondary outcomes are exploratory and unadjusted
- Excluded patients with hypercapnia, so findings do not extend to COPD exacerbation
- Industry funding for device provision; authors report no control over analysis
Start high-flow oxygen early in hypoxemic failure
Early HFNO cut intubation by 12 points and improved oxygenation within 24 hours in adults with acute hypoxemic respiratory failure.
- One intubation was avoided for every 9 patients treated with HFNO instead of conventional oxygen.
- Mortality did not differ, so the decision rests on avoiding intubation and its complications.
Ready for your own paper?
Paste a PubMed link or upload the poster and get the same structure in under a minute.